The 100 Days Mission: a perspective on accelerating vaccine manufacturing for future pandemics

Area of Science:

• Vaccinology
• Pandemic Preparedness
• Pharmaceutical Manufacturing

Background:

• The
• 100 Days Mission
• seeks to drastically reduce vaccine development and manufacturing timelines during pandemics.
• The COVID-19 pandemic highlighted the need for rapid, large-scale vaccine production.
• Pfizer leaders' insights from the COVID-19 vaccine effort inform future pandemic response strategies.

Purpose of the Study:

• To identify critical enablers for rapid, large-scale pandemic vaccine manufacturing.
• To outline strategies for pharmaceutical companies and governments to achieve accelerated vaccine delivery.
• To inform preparedness for future pandemic threats.

Main Methods:

• Analysis of insights from Pfizer leaders involved in COVID-19 vaccine development and manufacturing.
• Examination of key factors influencing rapid pharmaceutical production.
• Review of governmental roles in supporting pandemic vaccine initiatives.

Main Results:

• Essential enablers for pharmaceutical companies include robust governance, secure supply chains, innovative production strategies, and maintained "warm" manufacturing capacity.
• Crucial government support involves regulatory harmonization, enhanced global surveillance, and improved logistics.
• A multi-faceted approach involving industry and government is vital for success.

Conclusions:

• Addressing identified enablers is critical for achieving the ambitious goals of the "100 Days Mission".
• Enhanced collaboration between pharmaceutical companies and governments can significantly improve pandemic vaccine manufacturing.
• Proactive preparation is essential for global health security against future pandemic threats.